CANF's SI was 115,300 shares in December as released by FINRA. Its down 33.33% from 300 shares previously. It is down 0.00% since December 7, 2016 and is. (NASDAQ:SAGE) hit a new 52-week high and has $164.39 target or 5.00% above today's $156.56 share price. The 1-year high was reported on Dec, 7 by Barchart.com. If the $164.39 price target is reached, the company will be worth $321.35M more. (NYSE:SR). The stock saw a move of 0.28% during the latest trading session. Using a broader approach, shares have been trading 111.28% off of the 200-day moving average. It has outperformed by 99.75% the S&P500. (NASDAQ:SAGE)'s stock has been 22.76% and 65.05% for the last 12 months. SAGE Therapeutics had 44 analyst reports since September 3, 2015 according to SRatingsIntel. BidaskClub cut shares of Sage Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, August 23rd. Therefore 88% are positive. Bnp Paribas Arbitrage Sa has invested 0% of its portfolio in Sage Therapeutics, Inc.
Here we'll take a quick glance at how the stock price is now trading in relation to some of its simple moving averages.
ILLEGAL ACTIVITY WARNING: "BMO Capital Markets Reiterates Outperform Rating for Sage Therapeutics (SAGE)" was originally published by TrueBlueTribune and is owned by of TrueBlueTribune. H.C. Wainwright initiated the shares of SAGE in report on Thursday, June 23 with "Buy" rating. Cowen & Co maintained the stock with "Buy" rating in Thursday, August 3 report.
This is Sage's second success in as many months. (NASDAQ:SAGE) earned "Buy" rating by Stifel Nicolaus on Thursday, November 2. Bank of New York Mellon Corp increased its position in Sage Therapeutics by 36.5% during the third quarter. (NASDAQ:SAGE) on Wednesday, December 14 to "Strong Buy" rating. Chardan Capital upgraded SAGE Therapeutics from a sell rating to a neutral rating and set a $60.00 price target on the stock in a report on Tuesday, February 14th. As per Thursday, December 7, the company rating was maintained by Leerink Swann. (NASDAQ:SAGE) on Tuesday, September 12 with "Buy" rating.
Any dysfunction to the receptors can cause a variety of central nervous system (CNS) disorders. The company's market cap is $2.58 billion. It now has negative earnings.
The Sage Therapeutics Inc. announced positive results from the Phase 2 clinical trial assessing for SAGE-217, its experimental drug to treat people with moderate to severe major depressive disorder (MDD).
Institutional investors now hold around $3.63 billion or 0% in SAGE stock. Its down 0.13, from 1.11 in 2017Q1. The company's quarterly revenue was up.0% compared to the same quarter last year. sell-side analysts anticipate that Sage Therapeutics will post -7.4 EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the company. Tocqueville Asset Lp reported 71,450 shares stake. Tiaa Cref Invest Management Lc stated it has 0.01% in Sage Therapeutics, Inc. Northwestern Mutual Wealth Mgmt Co holds 34 shares or 0% of its portfolio. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company's stock worth $96,558,000 after acquiring an additional 87,097 shares during the period. Sphera Funds owns 5,000 shares or 0.07% of their United States portfolio. Airain Ltd holds 0.06% or 17,281 shares in its portfolio. Susquehanna Intl Grp Ltd Liability Partnership stated it has 45,032 shares. Over the past week, shares are -0.80%. California Employees Retirement Systems has invested 0% in Sage Therapeutics, Inc. (NASDAQ:SAGE) were released by: Realmoney.Thestreet.com and their article: "Sage Therapeutics Skyrockets on Data for Depression Drug - Biotech Movers" published on December 07, 2017 as well as Schaeffersresearch.com's news article titled: "SAGE Therapeutics Options Traders Don't Buy Depression Drug Breakout" with publication date: December 07, 2017. Comml Bank Of America Corp De holds 0% of its portfolio in Sage Therapeutics, Inc. "We look for SAGE to discuss Phase 3 plans during 2018", Newman surmises, quite confident on this depression asset's potential. Qs Investors Limited Liability Company holds 800 shares or 0% of its portfolio. (NASDAQ:SAGE). Moreover, Farallon Cap Ltd Liability Co has 0.08% invested in Sage Therapeutics, Inc. (NASDAQ:SAGE). 3,111 are owned by Brown Advisory.
Buscar Company focuses on buying, breeding, racing, and selling thoroughbreds.